Indicating that the PSU’s in pharma were critical for health security for the masses, the government said that sick PSU’s will not be sold
Indicating that the PSU’s in pharma were critical for health security for the masses, the government said that sick PSU’s will not be sold, but an effort will be made to re-energise and revive them by leveraging their existing assets.
The Minister of Chemicals and Fertilisers Ananth Kumar was speaking on the inauguration of the modernised general tablet section of IDPL Gurgaon Plant, which has been upgraded at a cost of Rs 3 crore.
“After modernisation, IDPL-Gurgaon plant will be able to launch new products in areas of diabetes, oncology, NSAIDS, antibiotics-3rd generation, nephrology and cardiology, including other segments of lifestyle diseases at affordable price…,” an official statement said.
As reported by PTI
There are five central PSUs in pharma sector. They are Karnataka Antibiotics & Pharmaceuticals Ltd (KAPL), Rajasthan Drugs and Pharmaceuticals Ltd (RDPL), Hindustan Antibiotics Ltd (HAL), Bengal Chemicals & Pharmaceuticals Ltd (BCPL) and Indian Drugs and Pharmaceuticals Ltd (IDPL).
Out of the five while KAPL and RDPL have been making profits but the other three — HAL, BCPL and IDPL — were declared sick by the Board for Industrial & Financial Reconstruction (BIFR). The government has been considering and working on various schemes for their revival.